The Front Room — a clinical regulatory commons
RSS
← Back to The Docket
MAY 15 2026
APPROVED · 77 DAYS AGO

Krystal Biotech Vyjuvek (beremagene geperpavec) $KRYS

for dystrophic epidermolysis bullosa

BLA

MHRA approved beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa.

About

Dystrophic epidermolysis bullosa is an inherited disease that causes extremely fragile skin and painful blisters from minor friction or trauma. Vyjuvek is a topical gene therapy that delivers a working copy of the collagen-producing gene directly to skin wounds. By helping skin cells produce the essential collagen they lack, this treatment may promote durable wound healing and reduce the burden of recurrent blisters.

Pivotal trial

GEM-3 Phase 3 completed NCT04491604

To determine whether administration of topical B-VEC improves wound healing as compared to placebo, and to evaluate durability, repeat dosing (Primary Endpoint) and further obtain safety and tolerability data.

Source: ClinicalTrials.gov

Also in development